Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer

BJU International

Volumn 103, Issue 4, 2009, Pages 547-552

  Li, Yongnan ^a   Li, Xiaoxia ^a   Dai, Haiping ^a   Sun, Xiaodong ^b   Li, Jinhua ^a   Yang, Fenghua ^a   Gu, Hongmei ^a   Yang, Yong ^a   Jin, Zaishun ^b   Chu, Yanhui ^c   Jin, Xiudong ^c   Kakehi, Yoshiyuki ^d   Wu, Xiuxian ^d  

^a MUDANJIANG MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c College of Heilongjiang Province   (China)

^d KAGAWA UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Prognosis; Thymidylate synthase

Indexed keywords

FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BLADDER; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 59249103886     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08099.x     Document Type: Article

References (30)

1. Zhang W, Xiang YB, Liu ZW et al. [Trends analysis of common urologic neoplasm incidence of elderly people in Shanghai, 1973-1999]. Ai Zheng 2004 23 : 555 8
2. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000 163 : 73 8
3. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmetre-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002 168 : 1964 70
4. Danenberg PV. Thymidylate synthase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977 473 : 73 92
5. Kubota Y, Hosaka M, Fukushima S, Kondo I. Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 1993 71 : 1842 5
6. Foekens JA, Romain S, Look MP, Martin PM, Klijn JG. Thymidylate kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 2001 61 : 1421 5
7. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994 12 : 2640 7
8. Chu E, Grem JL, Johnston PG, Allegra CJ. New concepts for the development and use of antifolates. Stem Cells 1996 14 : 41 6
9. Kamoshida S, Suzuki M, Shimomura R et al. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 2007 96 : 277 83
10. Edler D, Kressner U, Ragnhammar P et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of recurrence. Clin Cancer Res 2000 6 : 488 92
11. Li Y, Mizutani Y, Shiraishi T et al. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. Urology 2007 69 : 988 95
12. Mizutani Y, Wada H, Yoshida O et al. Significance of thymidylate synthase in renal cell carcinoma. Clin Cancer Res 2003 9 : 1453 60
13. Nomura T, Nakagawa M, Fujita Y, Handa T, Mimata H, Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 2002 9 : 368 76
14. Hashimoto H, Ozeki Y, Sato M et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006 106 : 1595 601
15. Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003 21 : 815 9
16. Inoue T, Segawa T, Shiraishi T et al. High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase. BJU Int 2006 98 : 197 200
17. Ceppi P, Volante M, Ferrero A et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008 14 : 1059 64
18. Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K, Itakura M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 2002 13 : 75 85
19. Shiga H, Heath E, Rasmussen A et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999 5 : 4097 104
20. Pestalozzi BC, Peterson HF, Gelber RD et al. Prognostic significance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997 15 : 1923 31
21. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal cancer and gastric tumors. Cancer Res 1995 55 : 1407 12
22. van Triest B, Pinedo HM, Blaauwgeers JL et al. Prognostic role of thymidylate synthase, thymidylate phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Caner Res 2000 6 : 1063 72
23. Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombination parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferation cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992 168 : 357 63
24. Huang C, Liu D, Masuya D et al. Clinical application of biological markers for treatments of respectable non-small-cell lung cancers. Br J Cancer 2005 92 : 1231 9
25. Bonfil RD, Gonzalez AD, Siguelboim D et al. Immunohistochemical analysis of Ki-67, 21waf1/cip 1 and apoptosis in marker lesions from patients with superficial bladder tumors treated with vinorelbine intravesical therapy in a preliminary phase I trial. BJU Int 2001 88 : 425 31
26. Kastanos EK, Zajac-Kaye M, Dennis PA, Allegra CJ. Down-regulation of p21/WAF1 expression by thymidylate synthase. Biochem Biophys Res Commun 2001 285 : 195 200
27. Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998 4 : 1243 50
28. Mohiuddin M, Chendil D, Dey S et al. Influence of p53 status on radiation and 5-flurouracil synergy in pancreatic cancer cells. Anticancer Res 2002 22 : 825 30
29. Allegra C. Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002 20 : 1711 3
30. Etienne M, Chazal M, Laurent-Puig P. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002 15 : 2832 43